Zhu D - Search Results

1

Clinical cancer immunotherapy: Current progress and prospects.

Liu C, Yang M, Zhang D, Chen M, Zhu D. Liu C, et al. Among authors: zhu d. Front Immunol. 2022 Oct 11;13:961805. doi: 10.3389/fimmu.2022.961805. eCollection 2022. Front Immunol. 2022. PMID: 36304470 Free PMC article. Review.

2

Targeting the tumour immune microenvironment for cancer therapy in human gastrointestinal malignancies.

Zhang Y, Xu J, Zhang N, Chen M, Wang H, Zhu D. Zhang Y, et al. Among authors: zhu d. Cancer Lett. 2019 Aug 28;458:123-135. doi: 10.1016/j.canlet.2019.05.017. Epub 2019 May 21. Cancer Lett. 2019. PMID: 31121212 Review.

3

Single-cell transcriptome analysis reveals tumor immune microenvironment heterogenicity and granulocytes enrichment in colorectal cancer liver metastases.

Zhang Y, Song J, Zhao Z, Yang M, Chen M, Liu C, Ji J, Zhu D. Zhang Y, et al. Among authors: zhu d. Cancer Lett. 2020 Feb 1;470:84-94. doi: 10.1016/j.canlet.2019.10.016. Epub 2019 Oct 11. Cancer Lett. 2020. PMID: 31610266

4

CRISPR-Cas9 genome editing for cancer immunotherapy: opportunities and challenges.

Chen M, Xu J, Zhou Y, Zhang S, Zhu D. Chen M, et al. Among authors: zhu d. Brief Funct Genomics. 2020 May 20;19(3):183-190. doi: 10.1093/bfgp/elz027. Brief Funct Genomics. 2020. PMID: 31788683

5

Cyclophilin A and CD147: novel therapeutic targets for the treatment of COVID-19.

Liu C, von Brunn A, Zhu D. Liu C, et al. Among authors: zhu d. Med Drug Discov. 2020 Sep;7:100056. doi: 10.1016/j.medidd.2020.100056. Epub 2020 Jul 16. Med Drug Discov. 2020. PMID: 32835213 Free PMC article. Review.

6

T-cell-based immunotherapy in colorectal cancer.

Feng M, Zhao Z, Yang M, Ji J, Zhu D. Feng M, et al. Among authors: zhu d. Cancer Lett. 2021 Feb 1;498:201-209. doi: 10.1016/j.canlet.2020.10.040. Epub 2020 Oct 29. Cancer Lett. 2021. PMID: 33129958 Review.

7

Discovery of a novel, potent and selective small-molecule inhibitor of PD-1/PD-L1 interaction with robust in vivo anti-tumour efficacy.

Liu C, Zhou F, Yan Z, Shen L, Zhang X, He F, Wang H, Lu X, Yu K, Zhao Y, Zhu D. Liu C, et al. Among authors: zhu d. Br J Pharmacol. 2021 Jul;178(13):2651-2670. doi: 10.1111/bph.15457. Epub 2021 May 4. Br J Pharmacol. 2021. PMID: 33768523 Free article.

8

Pharmacological Inhibition and Genetic Knockdown of BCL9 Modulate the Cellular Landscape of Cancer-Associated Fibroblasts in the Tumor-Immune Microenvironment of Colorectal Cancer.

Yang M, Wei Z, Feng M, Zhu Y, Chen Y, Zhu D. Yang M, et al. Among authors: zhu d, zhu y. Front Oncol. 2021 May 5;11:603556. doi: 10.3389/fonc.2021.603556. eCollection 2021. Front Oncol. 2021. PMID: 34026600 Free PMC article.

9

RORγt agonist synergizes with CTLA-4 antibody to inhibit tumor growth through inhibition of Treg cells via TGF-β signaling in cancer.

Tian EM, Yu MC, Feng M, Lu LX, Liu CL, Shen LA, Wang YH, Xie Q, Zhu D. Tian EM, et al. Among authors: zhu d. Pharmacol Res. 2021 Oct;172:105793. doi: 10.1016/j.phrs.2021.105793. Epub 2021 Jul 31. Pharmacol Res. 2021. PMID: 34339836

10

BCL9 regulates CD226 and CD96 checkpoints in CD8⁺ T cells to improve PD-1 response in cancer.

Feng M, Wu Z, Zhou Y, Wei Z, Tian E, Mei S, Zhu Y, Liu C, He F, Li H, Xie C, Jin J, Dong J, Yang D, Yu K, Qian J, Lambrechts D, Wang MW, Zhu D. Feng M, et al. Among authors: zhu d, zhu y. Signal Transduct Target Ther. 2021 Aug 20;6(1):313. doi: 10.1038/s41392-021-00730-0. Signal Transduct Target Ther. 2021. PMID: 34417435 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

11,119 results

Search Page